Re: Wolf...Verlon/darn1
in response to
by
Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.
Message: Re: Wolf...Verlon/darn1
Apr 03, 2007 11:28AM
This is from the last 10Q.(below) Note: Common stock authorized 500,000,000 shares. I don't think we have burned through all those yet have we? One never knows for sure. I don't see where they have requested any more in the proxy. The 53 million mentioned by Verlon on page 19 should come out(be issued) of that total right? There are currently 384+/-million outstanding, with 389+/- million issued, so there are still some available to issue, it would appear. Corrections welcome.
|
Stockholders’ equity:
|
|||||||
|
Preferred stock, $0.00001 par value; 5,000,000 shares authorized:
none outstanding
|
—
|
—
|
|||||
|
Common stock, $0.00001 par value: 500,000,000 shares authorized:
389,197,145 shares issued and 384,322,318 shares outstanding and
366,199,765 shares issued and outstanding
|
3,892
|
3,661
|
|||||
|
Additional paid-in capital
|
71,423,026
|
69,551,981
|
|||||
|
Accumulated deficit
|
(54,619,816
|
)
|
(58,728,091
|
)
|
|||
|
Common stock held in treasury, at cost - 4,874,827 shares and no shares
as of November 30, 2006 and May 31, 2006, respectively
|
(4,024,395
|
)
|
—
|
||||
|
Total stockholders’ equity
|
12,782,707
|
10,827,551
|
|||||
|
$
|
23,750,911
|
$
|
12,071,667
|
Loading...
Loading...
New Message
Please
login
to post a reply